Deerfield Management Company, L.P. (Series C) Vaxcyte, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $4.35 Billion
- Q2 2025
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 225,000 shares of PCVX stock, worth $10 Million. This represents 0.17% of its overall portfolio holdings.
Number of Shares
225,000
Previous 225,000
-0.0%
Holding current value
$10 Million
Previous $8.5 Million
13.91%
% of portfolio
0.17%
Previous 0.22%
Shares
3 transactions
Others Institutions Holding PCVX
# of Institutions
324Shares Held
139MCall Options Held
229KPut Options Held
160K-
Janus Henderson Group PLC London, X014.7MShares$655 Million0.25% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$535 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA12MShares$533 Million8.5% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$443 Million0.02% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD6MShares$267 Million0.12% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $2.64B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...